This is a working overview of fatty diacid chain, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-12-26 and is reviewed periodically as new material appears.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L-cells after food intake. It contains 31 amino acids and differs from native GLP-1 through modifications that slow enzymatic breakdown. The peptide was developed to extend the short circulating half-life of endogenous GLP-1, which is measured in minutes. Researchers introduced the compound in the early 2010s. Two backbone changes and a fatty acid side chain define its structure, distinguishing it from earlier GLP-1 receptor agonists.
The compound binds the GLP-1 receptor on pancreatic beta cells and other tissues, activating a G-protein signaling cascade that raises intracellular cyclic AMP. This action increases glucose-dependent insulin secretion when blood glucose is elevated, while binding also slows gastric emptying and reduces glucagon release. In the central nervous system, receptor activation in the hypothalamus and brainstem contributes to reduced appetite. The fatty acid chain binds albumin, which protects the peptide from renal filtration and enzymatic degradation. This albumin binding is central to its extended circulation time.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | free base, without counter-ion |
| Molecular weight | About 4114 Da | peptide backbone plus attached lipid chain |
| Plasma half-life | About 165 hours | supports once-weekly dosing in humans |
| Plasma protein binding | Greater than 99 percent | attributed mainly to serum albumin |
| Receptor target | GLP-1 receptor | Gs-coupled, raises intracellular cyclic AMP |
PCP has multiple routes of administration. Most commonly, the powder form of the drug is snorted. PCP can also be orally ingested, injected subcutaneously or intravenously, or smoked laced with marijuana or cigarettes.
=== Humans === Because branched chain amino acids are crucial in the formation and function of many proteins, BCATs have many responsibilities in mammalian physiology. BCATs have been found to interact with protein disulfide isomerases, a class of enzymes that regulate cellular repair and proper protein folding. The second step of branched chain amino acid metabolism (oxidative carboxylation by branched chain ketoacid dehydrogenase) stimulates insulin secretion. Loss of BCATm correlates with a loss in BCKD-stimulated insulin secretion, but has not been associated with losses in insulin secretion from other metabolic pathways. BCATc regulates the mTORC1 signaling and TCR-induced glycolytic metabolism pathways during CD4+ T cell activation. In the brain, BCATc regulates the amount of glutamate production for use as a neurotransmitter or for future γ-Aminobutyric acid (GABA) synthesis.
Until the 1970s there was considerable debate within psychiatry on the most appropriate term to use to describe the new drugs. In the late 1950s the most widely used term was "neuroleptic", followed by "major tranquilizer" and then "ataraxic". The first recorded use of the term tranquilizer dates from the early nineteenth century. In 1953 Frederik F. Yonkman, a chemist at the Swiss-based Cibapharmaceutical company, first used the term tranquilizer to differentiate reserpine from the older sedatives. The word neuroleptic was coined in 1955 by Delay and Deniker after their discovery (1952) of the antipsychotic effects of chlorpromazine. It is derived from the Greek: "νεῦρον" (neuron, originally meaning "sinew" but today referring to the nerves) and "λαμβάνω" (lambanō, meaning "take hold of"). Thus, the word means taking hold of one's nerves. It was often taken to refer also to common side effects such as reduced activity in general, as well as lethargy and impaired motor control. Although these effects are unpleasant and in some cases harmful, they were at one time, along with akathisia, considered a reliable sign that the drug was working. The term "ataraxy" was coined by the neurologist Howard Fabing and the classicist Alister Cameron to describe the observed effect of psychic indifference and detachment in patients treated with chlorpromazine. This term derived from the Greek adjective "ἀτάρακτος" (ataraktos), which means "not disturbed, not excited, without confusion, steady, calm".
Sources: en.wikipedia.org
Ménière's disease "Biologic disease-modifying antirheumatic drugs" This may not happen in the absence of infection. Atlanto-axial joint instability can cause symptoms including vertigo and sudden death. Atypical Cogan's syndrome may be associated with rheumoatoid arthritis.
(NH2)2CO → HNCO + NH3 Cyanic acid polymerizes to cyanuric acid, which condenses with the liberated ammonia forming melamine. The released water reacts with cyanic acid, which helps to drive the reaction:
Based on computational work by Bach, the strain energy for Z-cyclooctenes is 7.0 kcal/mol compared to 12.4 kcal/mol for cyclooctane due to a loss of two transannular interactions. E-cyclooctene has a highly twisted double bond resulting in a strain energy of 17.9 kcal/mol. As such, the highly strained trans-cyclooctene is used as a reactive dienophile. The diene is a 3,6-diaryl-s-tetrazine which has been substituted in order to resist immediate reaction with water. The reaction proceeds through an initial cycloaddition followed by a reverse Diels Alder to eliminate N2 and prevent reversibility of the reaction. Not only is the reaction tolerant of water, but it has been found that the rate increases in aqueous media. Reactions have also been performed using norbornenes as dienophiles at second order rates on the order of 1 M−1•s−1 in aqueous media. The reaction has been applied in labeling live cells and polymer coupling.
== Publications == 1922: Researches on the insect metamorphosis. Doctoral Thesis on the histology of metamorphosis of the Chalcid wasp, Nasonia. 1922: On the arrangement of the striations of voluntary muscle fibres in double spirals. 1932: "The Innervation of the Striated Musculature in Python", The Australian Journal of Experimental Biology and Medical Science, Vol.9, No.1, (January 1932), pp. 191-201. 1938: Memoirs: The Embryonic Development of Calandra oryzae. (with Florence V. Murray) see Sitophilus oryzae the rice weevil. 1942: The ‘Dorsal Organ’ of the Embryo of Campodea. 1945: Memoirs: The Post-Embryonic Development of Hanseniella agilis (Symphyla). 1947: The development and affinities of the Pauropoda, based on a study of Pauropus silvaticus. 1955: The Path of the Slow Contractile Wave in Arthropod Muscle Fibre. (with E. Matthaei) Photographic records are consistent with the hypothesis that the slow waves move along the helicoid.
Sources: en.wikipedia.org
Native GLP-1 is a short-lived peptide cleared within one to two minutes by dipeptidyl peptidase-4 and related enzymes. Semaglutide keeps the receptor-binding backbone but adds substitutions and a lipid chain. These changes block the main cleavage site and allow reversible albumin binding, extending the half-life to roughly 165 hours.
Albumin is the most abundant protein in plasma and carries molecules that bear fatty-acid chains. Binding shields the peptide from renal filtration and from peptidases, keeping a circulating reservoir. Slow release from this reservoir produces sustained receptor occupancy and supports infrequent dosing.
The insulinotropic effect is glucose-dependent, meaning secretion increases mainly when glucose is elevated. This property is often described as lowering the chance of hypoglycaemia when the compound is used alone. Other glucose-lowering agents used at the same time can still cause low blood glucose.
It is a synthetic analog of GLP-1 produced through medicinal chemistry to resist enzymatic degradation. The design goal was longer circulation than the native hormone.